500
Participants
Start Date
May 29, 2025
Primary Completion Date
May 31, 2029
Study Completion Date
March 31, 2030
Single Antiplatelet Therapy or No Therapy (Control)
Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.
Non-Antithrombotic Therapy
Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.
RECRUITING
Nagoya Heart Center, Nagoya
RECRUITING
Toyohashi Heart Center, Toyohashi
RECRUITING
New Tokyo Hospital, Matsudo
RECRUITING
Kokura Kinen Hospital, Kitakyushu
RECRUITING
Gifu Heart Center, Gifu
RECRUITING
Medical Corporation Sapporo Heart Center Sapporo Cardio Vascular Clinic, Sapporo
RECRUITING
Sapporo Higashi Tokushukai Hospital, Sapporo
RECRUITING
Tokai University Hospital, Isehara
RECRUITING
St.Marianna University Hospital, Kawasaki
RECRUITING
Sendai Kousei Hospital, Sendai
RECRUITING
Kurashiki Central Hospital, Kurashiki
RECRUITING
The Sakakibara Heart Institute of Okayama, Okayama
RECRUITING
Kindai University Hospital, Ōsaka-sayama
RECRUITING
Juntendo University Hospital, Bunkyo-ku
RECRUITING
Mitsui Memorial Hospital, Chiyoda-ku
RECRUITING
Sakakibara Heart Institute, Fuchū
RECRUITING
Teikyo University Hospital, Itabashi-ku
NOT_YET_RECRUITING
IMS Tokyo Katsushika General Hospital, Katsushika-ku
RECRUITING
Toho University Omori Medical Center, Ōta-ku
RECRUITING
Keio University Hospital, Shinjuku-ku
RECRUITING
Toyama University Hospital, Toyama
Collaborators (1)
Boston Scientific Corporation
INDUSTRY
OCEAN-SHD Study Group
OTHER